Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Sodium–glucose cotransporter 2 inhibitors and inflammation in chronic kidney disease: Possible molecular pathways
Habib Yaribeygi, Alexandra E. Butler, Stephen L. Atkin, et al.
Journal of Cellular Physiology (2018) Vol. 234, Iss. 1, pp. 223-230
Open Access | Times Cited: 129

Showing 1-25 of 129 citing articles:

11. Microvascular Complications and Foot Care: Standards of Medical Care in Diabetes−2020

Diabetes Care (2019) Vol. 43, Iss. Supplement_1, pp. S135-S151
Open Access | Times Cited: 406
Pathophysiology of diabetic kidney disease: impact of SGLT2 inhibitors
Ralph A. DeFronzo, William Reeves, Alaa S. Awad
Nature Reviews Nephrology (2021) Vol. 17, Iss. 5, pp. 319-334
Closed Access | Times Cited: 384
11. Microvascular Complications and Foot Care: Standards of Medical Care in Diabetes—2021

Diabetes Care (2020) Vol. 44, Iss. Supplement_1, pp. S151-S167
Open Access | Times Cited: 329
Sodium–glucose cotransporter type 2 inhibitors for the treatment of type 2 diabetes mellitus
André Scheen
Nature Reviews Endocrinology (2020) Vol. 16, Iss. 10, pp. 556-577
Closed Access | Times Cited: 228
Signaling pathways of chronic kidney diseases, implications for therapeutics
Qian Yuan, Ben Tang, Chun Zhang
Signal Transduction and Targeted Therapy (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 217
11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2023
Nuha A. ElSayed, Grazia Aleppo, Vanita R. Aroda, et al.
Diabetes Care (2022) Vol. 46, Iss. Supplement_1, pp. S191-S202
Open Access | Times Cited: 202
Sodium-Glucose Cotransporter 2 Inhibitors Mechanisms of Action: A Review
Jorge I. Fonseca‐Correa, Ricardo Correa‐Rotter
Frontiers in Medicine (2021) Vol. 8
Open Access | Times Cited: 150
An Overview of the Cardiorenal Protective Mechanisms of SGLT2 Inhibitors
Teresa Salvatore, Raffaele Galiero, Alfredo Caturano, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 7, pp. 3651-3651
Open Access | Times Cited: 145
11. Chronic Kidney Disease and Risk Management: Standards of Medical Care in Diabetes—2022

Diabetes Care (2021) Vol. 45, Iss. Supplement_1, pp. S175-S184
Closed Access | Times Cited: 138
Pharmacotherapy of type 2 diabetes: An update and future directions
Antea DeMarsilis, Niyoti Reddy, Chrysoula Boutari, et al.
Metabolism (2022) Vol. 137, pp. 155332-155332
Closed Access | Times Cited: 95
Oxidative stress and the role of redox signalling in chronic kidney disease
Seiji Kishi, Hajime Nagasu, Kengo Kidokoro, et al.
Nature Reviews Nephrology (2023) Vol. 20, Iss. 2, pp. 101-119
Closed Access | Times Cited: 88
Antihypertensive and Renal Mechanisms of SGLT2 (Sodium-Glucose Linked Transporter 2) Inhibitors
Christopher S. Wilcox
Hypertension (2020) Vol. 75, Iss. 4, pp. 894-901
Open Access | Times Cited: 122
Effects of newer antidiabetic drugs on nonalcoholic fatty liver and steatohepatitis: Think out of the box!
Golnaz Ranjbar, Dimitri P. Mikhailidis, Amirhossein Sahebkar
Metabolism (2019) Vol. 101, pp. 154001-154001
Closed Access | Times Cited: 94
Serum Uric Acid and Diabetes: From Pathophysiology to Cardiovascular Disease
Niki Katsiki, George Dimitriadis, Dimitri P. Mikhailidis
Current Pharmaceutical Design (2021) Vol. 27, Iss. 16, pp. 1941-1951
Closed Access | Times Cited: 86
Emergence of SGLT2 Inhibitors as Powerful Antioxidants in Human Diseases
Kai‐Fan Tsai, Yung‐Lung Chen, Terry Ting-Yu Chiou, et al.
Antioxidants (2021) Vol. 10, Iss. 8, pp. 1166-1166
Open Access | Times Cited: 79
Anti-inflammatory properties of antidiabetic drugs: A “promised land” in the COVID-19 era?
Niki Katsiki, Ele Ferrannini
Journal of Diabetes and its Complications (2020) Vol. 34, Iss. 12, pp. 107723-107723
Open Access | Times Cited: 78
Obesity‐related glomerulopathy: Current approaches and future perspectives
José Ignacio Martínez‐Montoro, Enrique Morales, Isabel Cornejo‐Pareja, et al.
Obesity Reviews (2022) Vol. 23, Iss. 7
Open Access | Times Cited: 60
Cardiovascular outcomes trials: a paradigm shift in the current management of type 2 diabetes
Melanie J. Davies, Heinz Drexel, François R. Jornayvaz, et al.
Cardiovascular Diabetology (2022) Vol. 21, Iss. 1
Open Access | Times Cited: 44
Empagliflozin Ameliorates Bleomycin-Induced Pulmonary Fibrosis in Rats by Modulating Sesn2/AMPK/Nrf2 Signaling and Targeting Ferroptosis and Autophagy
Hemat El‐Sayed El‐Horany, Marwa Mohamed Atef, Muhammad Tarek Abdel Ghafar, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 11, pp. 9481-9481
Open Access | Times Cited: 33
Molecular mechanisms by which SGLT2 inhibitors can induce insulin sensitivity in diabetic milieu: A mechanistic review
Habib Yaribeygi, Thozhukat Sathyapalan, Mina Maleki, et al.
Life Sciences (2019) Vol. 240, pp. 117090-117090
Open Access | Times Cited: 69
A review of the anti‐inflammatory properties of antidiabetic agents providing protective effects against vascular complications in diabetes
Habib Yaribeygi, Stephen L. Atkin, Matteo Pirro, et al.
Journal of Cellular Physiology (2018) Vol. 234, Iss. 6, pp. 8286-8294
Closed Access | Times Cited: 62
Renal Outcomes in Type 2 Diabetes: A Review of Cardiovascular and Renal Outcome Trials
David M. Williams, Asif Nawaz, Marc Evans
Diabetes Therapy (2019) Vol. 11, Iss. 2, pp. 369-386
Open Access | Times Cited: 59
Neuromodulatory effects of anti-diabetes medications: A mechanistic review
Habib Yaribeygi, Milad Ashrafizadeh, Neil C. Henney, et al.
Pharmacological Research (2019) Vol. 152, pp. 104611-104611
Closed Access | Times Cited: 59
Comparison of Sodium-Glucose Cotransporter 2 Inhibitors vs Glucagonlike Peptide-1 Receptor Agonists and Incidence of Dry Eye Disease in Patients With Type 2 Diabetes in Taiwan
Yu‐Chen Su, Jia‐Horung Hung, Kai‐Cheng Chang, et al.
JAMA Network Open (2022) Vol. 5, Iss. 9, pp. e2232584-e2232584
Open Access | Times Cited: 35
Preventive empagliflozin activity on acute acetic acid-induced ulcerative colitis in rats via modulation of SIRT-1/PI3K/AKT pathway and improving colon barrier
Marwa S. Zaghloul, Mahmoud Elshal, Marwa E. Abdelmageed
Environmental Toxicology and Pharmacology (2022) Vol. 91, pp. 103833-103833
Closed Access | Times Cited: 33
Page 1 - Next Page

Scroll to top